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Abstract  
Rheumatoid arthritis is an autoimmune disease characterized by chronic joint inflammation 
and progressive destruction of cartilage and bone which leads to ultimately loss of function 
and pain. Activated synovial fibroblasts are key effector cells in the pathogenesis of 
rheumatoid arthritis. In the recent years, epigenetic changes including DNA methylation, 
histone acetylation and other histone modifications were identified that are associated with 
an intrinsic activation and the aggressive phenotype of these cells. So far, no therapies 
targeting rheumatoid arthritis synovial fibroblasts exist. This review comprises recent 
research efforts that propose epigenetic mechanisms behind the activation of rheumatoid 
arthritis synovial fibroblasts and other cell types.  
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Rheumatoid arthritis (RA) is an autoimmune disease characterized by a systemic 
inflammation, joint destruction, disability and pain. Despite enormous research efforts the 
underlying cause of the disease is unknown and still no cure exists. Joint resident 
rheumatoid arthritis synovial fibroblasts (RASF) emerged as key players in the pathogenesis 
of RA. In addition to macrophages and lymphocytes, also RASF are capable of producing a 
large set of inflammatory cytokines and chemokines and thereby actively contribute to the 
inflammatory state in RA. Their intrinsic activation, the inhibition of apoptosis and the 
recruitment of inflammatory cells including macrophages and lymphocytes, are the major 
reasons for the excessive hyperplasia of the synovial tissue in RA joints [1]. The importance 
of these cells in disease progression was further emphasized by functional studies of RASF 
in the severe immune deficient (SCID) mouse model; RASF, co-implanted with cartilage 
under the renal capsule of SCID mice were shown to be capable not only to invade into 
cartilage in the absence of a functioning immune system but also to migrate [2].  
This review comprises recent research efforts that reveal the mechanisms behind the 
intrinsic activation of RASF by investigating epigenetic changes (Figure 1) and summarizes 
data available from other cell types.  
What is epigenetics? 
Originally, epigenetic mechanisms were considered as heritable changes in gene function 
that were not explainable by changes in the DNA sequence. A more revised definition of 
epigenetics is the structural adaption of chromosomal regions in order to register, signal or 
perpetuate altered activity states [3]. Epigenetic modifications including DNA methylation and 
covalent histone modifications such as acetylation, methylation and ubiquitination alter the 
accessibility of DNA to the transcription machinery. An increasing amount of proteins that 
attach (“writers”) or remove (“erasers”) modifications to DNA and histones or that bind 
(“readers”) to a specific epigenetically modified site have emerged as key players in the 
regulation of gene expression [4]. Most chromatin marks are highly dynamic and have the 
capability of influencing transcription by multiple mechanisms; first, they designate chromatin 
structure and therefore, determine the accessibility of DNA for regulatory proteins; second, 
they recruit remodeling enzymes that utilize the hydrolysis of ATP to reposition nucleosomes; 
and third, they mediate the cooperation between pioneer and secondary transcription factors 
[5].  
Most research so far focused on the role of 5-methylcytosine (5-mC) in CpG-rich regions, 
known as CpG islands. CpG islands are enriched in promoters in vicinity to transcriptional 
start sites and their methylation has been associated with long term gene silencing including 
X-chromosome inactivation.  Methylation of DNA is regulated by the activity of DNA methyl 
transferases (DNMTs) [6].  
Histone acetylation on lysines is regulated by the opposing activity of two enzyme families, 
histone acetyl transferases (HATs) and histone deacetylases (HDACs). Histone acetylation 
neutralizes lysine`s positive charges, an action that has the potential to weaken the 
interactions between DNA and histones. HDACs are thought to stabilize the local chromatin 
structure by restoring the positive charges in lysine residues. Therefore, they are mainly 
considered as transcriptional repressors [5].  
Unlike acetylation, histone methylation does not alter the charge of histone proteins. Histone 
methylation mainly occurs at lysine and arginine residues of histones H3 and H4 which can 
be mono-, di- (lysines, arginines) and trimethylated (lysines) [5]. Depending on the position 
and the degree of methylation, histone methylation marks can be associated with 
transcriptional activation or silencing. The polycomb repressive complex 2 with its enzymatic 
subunit histone methyltransferase enhancer of zeste homologue 2 (EZH2) is responsible for 
the trimethylation of the repressive mark H3K27me3 (Histone 3 lysine 27 trimethylation) [7]. 
Today two families of proteins, the lysine-specific demethylase family and the Jumonji C 
family are known to have histone demethylase activity [8].  
In contrast to the above described histone modifications, histone ubiquitination and 
sumoylation result in larger covalent modifications of histones. Whereas ubiquitination can be 
associated with transcriptional silencing, as well as with transcriptional initiation and 
elongation, histone sumoylation is associated with repressive functions. Sumoylation targets 
mainly histone lysines that are modified by the action of E1, E2, and E3 enzymes which 
covalently attach small ubiquitin-like modifier molecules (SUMO) [5]. 
In the following sections we discuss recent findings on the impact of DNA methylation and 
histone modifications studied so far in the context of RA (Figure 2, Table 1). 
DNA methylation  
RASF display a DNA methylome signature that distinguishes them from osteoarthritis 
synovial fibroblasts (OASF) and normal SF [9,10]. Whereas Karouzakis et al. described a 
global hypomethylation in RASF compared to OASF [9], Nakano et al. investigated both 
hypo- and hypermethylation patterns in RASF [10]. A global hypomethylation was also found 
in peripheral blood mononuclear cells (PBMCs) isolated from RA patients compared to 
healthy controls [11]. Hypomethylation was identified in key genes relevant for RA and 
related to multiple pathways including cell migration, adhesion, transendothelial migration 
and extracellular matrix interactions and was associated with an increased gene expression 
[10]. Interestingly, DNMT1, the active enzyme in somatic cells for converting cytosine into 5-
methylcytosine (5-MeC) using S-adenosyl methionine (SAM) as a methyl-donor, is reduced 
in RASF compared to OASF [9]. Furthermore, an increased expression of S-adenosyl 
methionine decarboxylase (AMD), spermidine/ spermine N1-acetyltransferase (SSAT1) and 
of polyamine-modulated factor 1-binding protein 1 (PMFBP1) led to an increased recycling of 
polyamines and a reduced amount of SAM and 5-MeC, and was associated with 
hypomethylation in RASF [12]. Beside global changes in methylome signatures in RA, an 
altered methylation status of single gene promoters, including promoters for DR3 [13], IL6 
[14,15], IL10 [16,17], IL1R2 [17] and CXCL12 [18] was described in PBMCs and RASF. 
Further evidence for the role of DNA methylation in the pathogenesis of RA and a possible 
explanation for the increased risk of women to develop RA came from studies investigating 
the pattern of X-chromosome inactivation. Female RA patients exhibited an increased 
skewed X-chromosome inactivation pattern compared to controls [19] and the promoter of 
the X chromosome encoded gene CD40L was demethylated in CD4+ T cells from female but 
not male RA patients [20].  These data clearly show a functional consequence of altered 
DNA methylation patterns in RA. The results from Karouzakis et al. [9,12] suggested that a 
supplementation with SAM and/ or the inhibition of the polyamine recycling pathway could be 
a new promising therapeutic strategy in the treatment of RA and the first therapy that targets 
the intrinsically activated phenotype found in RASF. 
Histone methylation  
Studies looking at histone methylation in the context of RA are scarce. The histone 
methyltransferase EZH2 was shown to be overexpressed in RASF compared to OASF [21]. 
EZH2 generates the trimethyl mark on histone 3 lysine 27 (H3K27me3) which is associated 
with the transcriptional silencing of genes [7]. The tumor suppressor gene secreted frizzled-
related protein 1 (SFRP1), an inhibitor of the wingless type MMTV integration site (Wnt) 
signaling pathway, was show to be a target of EZH2 activity in RASF. EZH2 overexpression 
had no impact on global histone trimethylation in RASF [21]. Recently, the involvement of 
H3K27me3 marks in the pathogenesis of systemic lupus erythematous (SLE) [22] and 
systemic sclerosis (SSc) [23] were reported. Further studies in RA are needed to clarify the 
role of histone methylation marks in this autoimmune disease. 
Histone acetylation  
In the last eight years certain beneficial effects of HDAC inhibitors in therapeutic as well as 
preventive approaches in different animal models of RA have been reported [24-28]. 
Although some decrease in disease severity was shown, these studies have in common that 
the used inhibitors lack specificity for a single HDAC isoform and the underlying mechanisms 
remained obscure. Also, there are some discrepancies in the literature about HDAC 
expression and activity in synovial tissues of RA and OA patients [29,30], as well as in RASF 
[31]. Recently, Kawabata et al. reported that TNF-α increased the expression of HDAC1 and 
nuclear HDAC activity in RASF [30], suggesting that changes in synovial HDAC activity 
maybe secondary to local inflammatory changes [32]. Also, Niederer et al. discovered that 
Sirtuin 1 (SIRT1), a member of the NAD+ dependent Class III histone deacetylases, is over 
expressed in RA tissues and expression levels were further increased by stimulation of 
RASF with TNF-α. The authors convincingly showed that SIRT1 overexpression promoted 
the pro-inflammatory cytokine production in monocytes and RASF, and inhibited apoptosis in 
RASF [33]. Several recent studies investigated effects of different HDAC inhibitors in vitro. 
The HDAC3 specific inhibitor MI192 was shown to inhibit the LPS-induced expression of 
TNF-α and IL1-β in PBMCs derived from RA patients and healthy controls [34]. The Class I 
and Class II HDAC inhibitor trichostatin A (TSA) as well as the Class III HDAC inhibitor 
nicotinamide reduced the TNF-α-induced expression of IL6 and the LPS-stimulated 
expression of IL6 and TNF-α in macrophages of RA patients. Interestingly, this study could 
not confirm an association between the HDAC inhibitor-dependent acetylation of H3 and H4 
and the ability of these HDAC inhibitors to regulate cytokine production in macrophages [35]. 
A growing number of non-histone proteins has been identified as targets for acetylation 
including signaling molecules, transcription factors and structural proteins. Reversible lysine 
acetylation in these proteins regulates cellular processes such as the control of mRNA 
stability, protein localization and degradation, protein-protein as well as protein-DNA 
interactions [36]. Recently, Grabiec et al. reported that the HDAC inhibitors TSA and ITF2357 
reduced IL6 mRNA stability in macrophages and RASF. However, the identified mechanism 
was not applicable for the regulation of IL8 and MMP1 [37]. Furthermore, the HDAC 
inhibitors MS-275 and SAHA suppressed the LPS-induced nuclear accumulation of NF-КB 
p65 in human rheumatoid arthritis synovial fibroblastic E11 cells and THP1 monocytes [38]. 
These results point to the fact that not all observed beneficial effects of HDAC inhibitors in 
vitro and in vivo are due to epigenetic modifications and that there is a variety and likely 
gene-specific mode of action of different HDAC inhibitors on defined target genes. 
Furthermore, nutritional influences might significantly alter the state of acetylation. For 
example, three to six hours after broccoli sprout consumption HDAC activity is reduced and 
H3 and H4 acetylation are modulated [39].  
Other histone modifications  
So far, only one report exists investigating the functional interaction of sumoylation and 
epigenetic changes in RASF. RASF have intrinsically high levels of the small ubiquitin like 
modifier (SUMO)-1 paralleled by decreased levels of its specific protease SENP1. Transient 
overexpression of SENP1 in RASF reduced H4 acetylation in the MMP1 promoter and 
consequently MMP1 expression, leading to a decreased invasiveness. The authors further 
showed that the mechanism was dependent on the presence of HDAC4 [40].  
With respect to the epigenetic modifications regulated by microRNAs we refer to our latest 
review on this subject [41]. 
Conclusions 
In recent years, altered DNA methylation patterns and histone modifications including 
acetylation, methylation and sumoylation emerged as contributors in the pathogenesis of RA. 
The field of epigenetics has great potential of finding completely new targets for the 
treatment of RA. So far, most results are based on in vitro data and only little information 
exists about in vivo mechanisms. Available in vivo studies are based on the usage of HDAC 
inhibitors, which have, as recent in vitro studies showed, many non-epigenetic effects. For 
many histone modifications the data about their role in the pathogenesis of RA is insufficient 
and there is a complete lack of information about the interaction of different epigenetic 
mechanisms. Based on available evidence, targeting the aberrant methylation pattern found 
in RASF appears a promising treatment option to reverse the intrinsic activation, although in 
vivo work needs to be done to confirm this.  
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Figure 1: Epigenetic modifications such as DNA methylation and histone modifications of 
rheumatoid arthritis synovial fibroblasts (RASF) contribute to their intrinsic activation and 
aggressive phenotype. ac, acetylation; me; methylation; su, sumoylation; 
 
Figure 2: Epigenetic mechanisms and downstream targets identified in rheumatoid synovial 
fibroblasts, macrophages and peripheral blood mononuclear cells (PBMCs). HDACs, histone 
deacetylases; SIRT1, Sirtuin1; LPS, lipopolysaccharide; IL, interleukin; TNF-α, tumor 
necrosis factor-α; EZH2, histone methyltransferase enhancer of zeste homologue 2; SFRP1, 
secreted frizzled-related protein 1; SENP1, SUMO specific protease 1; MMP1, 
metalloproteinase 1; SSAT, spermidine/ spermine N1-acetyltransferase; PMFBP1, 
polyamine-modulated factor 1-binding protein 1; AMD1, S-adenosyl methionine 
decarboxylase; DNMT1, DNA methyltransferase 1; SAM, S-adenosyl methionine; 5-MeC, 5-
methylcytosine; CXCL12, chemokine (C-X-C motif) ligand 12; CD40 L, CD40 ligand;  
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Table 1: Experimentally used drugs targeting epigenetic modifications in rheumatoid arthritis. 
 
Highlights 
 RA synovial fibroblasts display an aberrant DNA methylome signature  
 Histone deacetylase inhibitors have beneficial effects in RA  
 Histone deacetylase inhibitors have epigenetic and non-epigenetic effects 
 
